Do you think that the kind and apparently generous folks over at Roche would be interested in an acquisition that would give them a nice little inroads into the CML market and a potentially ass-kicking ALK/EGFR inhibitor to boot?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.